Clinical application of doxorubicin to cancers with the highest or lowest levels of CREB3L1 expression.

Cancers with the highest or lowest levels of CREB3L1 mRNA were identified through bioinformatics analysis of the Oncomine database. To search for these cancers, p-values were set to less than 10−4 to minimize variation in CREB3L1 expression among individual tumors in a given type of cancer, and fold of changes were set to more than 3 to select tumors in which levels of CREB3L1 mRNA is at least 3 times higher or lower than the average value of the mRNA across all the tumors deposited into the database. Tumors were ordered by Oncomine according to combined evaluation of fold of changes and p-values. American Cancer Society (www.cancer.org) and National Cancer Institute (www.cancer.gov) were consulted to obtain information regarding clinical application of doxorubicin to each cancer.A Doxorubicin is used as a non-standard treatment for ovarian cancers in general, but its effect on ovarian mucinous adenocarcinoma has not been determined.Clinical application of doxorubicin to cancers with the highest or lowest levels of CREB3L1 expression.